Top Ten most popular articles on Pharmafile.com this week

pharmafile | January 10, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

The US pharamaceutical industry dominates the news this week, with Pfizer, Sanofi and GlaxoSmithKline all increasing their drug prices while Novo Nordisk is offering its US patients free insulin.

Staying with America, the link between talc powder and ovarian cancer has been cast in to doubt, with the largest study of its kind concluding their is no link between them.

10. FDA gives a priority review for key heart failure drug Farxiga

The FDA has accepted a New Drug Application (sNDA) and has granted a priority review for AstraZeneca’s drug Farxiga (dapagliflozin) to reduce the risk of heart failure (HF) and cardiovascular death.

9. Teva to settle bribery lawsuit with $54 million payout

Israeli drug firm Teva has agreed to settle an ongoing lawsuit levying allegations of the company’s bribery of doctors, it has emerged, with the payment of $54 million.

8. No link between talc and ovarian cancer, new study reveals

Researchers examining data from over 252,000 women have concluded that there is no statistically significant link between the use of talc-based baby powder and ovarian cancer.

7. MSD’s Keytruda chalks up bladder cancer approval in the US

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded marketing authorisation to the therapy for the treatment of a specific form of bladder cancer.

6. Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020

Multiple drugmakers, including Pfizer, Sanofi and GlaxoSmithKline, plan to increase US list prices on more than 200 drugs in the United States.

5. Diabetes drug could increase stem cells in the womb to treat recurrent miscarriage

A study led by the University of Warwick found that sitagliptin, a diabetes drug, could be used to treat recurrent miscarriage by targeting the lining of the womb.

4. Novartis’ ligelizumab tops Xolair in chronic spontaneous urticarial

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair (omalizumab), also manufactured by the company, in the treatment of the skin condition chronic spontaneous urticaria (CSU).

3. Johnson & Johnson sued by Washington State for role in the opioid crisis

The state of Washington sued pharmaceutical company Johnson & Johnson for deceptive marketing that said their opioids were effective for treating pain and being unlikely to be addictive.

2. NICE rules against the use of Akcea’s Waylivra in the NHS

NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in the National Health Service (NHS) in England

1. Novo Nordisk to offer US patient’s in immediate need free insulin

Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices.

Related Content

No items found

Latest content